Name | RIP2 kinase inhibitor 2 |
---|---|
Synonyms |
4-Quinolinamine, 6-[(1,1-dimethylethyl)sulfonyl]-N-(4,5-dimethyl-1H-pyrazol-3-yl)-7-(2-methoxyethoxy)-
N-(4,5-Dimethyl-1H-pyrazol-3-yl)-7-(2-methoxyethoxy)-6-[(2-methyl-2-propanyl)sulfonyl]-4-quinolinamine |
Description | RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9. |
---|---|
Related Catalog | |
Target |
RIP2 Kinase[1] |
In Vitro | RIP2 kinase inhibitor 2 is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor interacting protein-2 (RIP2) kinase is a TKL family serine/threonine protein kinase involved in innate immune signaling. Following activation, RIP2 kinase associates with NODI or NOD2 and appears to function principally as a molecular scaffold to bring together other kinases (TAK1, ΙΚΚα/β/γ) involved in NF-κΒ and mitogen-activated protein kinase activation[1]. |
Animal Admin | Rats[1] Rats are orally pre-dosed with the RIP2 kinase inhibitor 2, at doses of 0.016, 0.16 and 1.6 mg/kg (n=8 rats/group), followed by dosing with L18-MDP (50 μg/rat) 0.25 hours after pre-dosing with the compound. The IL8 cytokine levels and percentage levels are calculated as the mean±standard error of the mean (n=8 rats/group). |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 670.0±55.0 °C at 760 mmHg |
Molecular Formula | C21H28N4O4S |
Molecular Weight | 432.536 |
Flash Point | 359.0±31.5 °C |
Exact Mass | 432.183136 |
LogP | 3.27 |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.595 |
Storage condition | 2-8℃ |